

# Correspondence



## INSTRUCTIONS FOR LETTERS TO THE EDITOR

Editorial comment in the form of a Letter to the Editor is invited. The length of a letter should not exceed 800 words, with a maximum of 10 references and no more than 2 figures or tables; and no subdivision for an abstract, methods, or results. Letters should have no more than 4 authors. Financial associations or other possible conflicts of interest should be disclosed.

Letters should be submitted via our online submission system, available at the Manuscript Central website: <http://mc.manuscriptcentral.com/jrheum> For additional information, contact the Managing Editor, The Journal of Rheumatology, E-mail: [jrheum@jrheum.com](mailto:jrheum@jrheum.com)

## Anemia of Chronic Disease in Patients with Rheumatoid Arthritis — Use of Zinc Protoporphyrin (ZPP) Levels

To the Editor:

We read with interest the editorial by Swaak<sup>1</sup> on anemia of chronic diseases in patients with rheumatoid arthritis (RA). The article points out that the anemia of chronic disease is the most frequent cause of anemia in RA, and that the most reliable indicator for the detection of iron deficiency is stainable iron content in bone marrow aspirate. In practical terms, however, this procedure may not be routinely performed in patients suspected clinically to have iron deficiency. We wish to draw attention to the role of measuring zinc protoporphyrin (ZPP) concentrations.

Chronic disorders are frequently accompanied by impairment of iron metabolism<sup>2</sup>. There are various blood tests that can be done to elucidate iron deficiency in RA, including serum ferritin, mean corpuscular volume (MCV), and serum transferrin receptor levels, as reviewed by Swaak. The serum ferritin level is not a reliable indicator of iron deficiency, as it is an acute phase reactant and the level may be elevated in RA. MCV can also be affected by the second-line treatment for RA (e.g., azathioprine, salazopyrin, methotrexate), which can increase the MCV. Coexisting morbidity (e.g., hypothyroidism, B12, folate deficiency, and alcohol abuse) could also influence results.

The use of ZPP level in blood to diagnose iron deficiency anemia in RA has received limited attention. Red cell precursors normally synthesize slightly more protoporphyrin than is needed for heme synthesis. The excess remains with the cell throughout its lifespan and has been called free erythrocyte protoporphyrin (FEP). When iron is not available for heme synthesis protoporphyrin accumulates in excess as zinc protoporphyrin. The level of FEP increases dramatically in iron deficiency and is a sensitive laboratory abnormality<sup>2</sup>.

The ZPP determination is simple and also appears to provide a sensitive index of iron-deficient erythropoiesis<sup>3</sup>. Currently it is used to differentiate between iron deficiency, beta thalassemia, and lead poisoning<sup>4</sup>. ZPP level is also used as a screening tool for iron deficiency anemia in hospitalized patients<sup>5</sup>.

ZPP levels are elevated in iron-deficient erythropoiesis, which can be associated with iron deficiency and anemia of chronic diseases.

In one study the ZPP level returned to normal after successful treatment of the underlying disease, which included polymyalgia rheumatica<sup>6</sup>. Those patients had typical laboratory findings of iron deficiency including low iron, decreased transferrin saturation, and decreased bone marrow sideroblasts, and also strongly elevated ZPP level.

As the editorial points out, anemia appears to be associated with poor outcome in patients with RA. We believe that further work in assessing the role of measuring ZPP in patients with RA to give a noninvasive indicator of the degree of poor iron utilization and heme synthesis would also be merited. This would particularly be helpful when the response to treatment is being assessed. The cost of testing ZPP level is also relatively low.

SHANMUGAM SARAVANA, MRCP(UK); ASHOK RAI, FRCP(UK),  
Department of Rheumatology, Worcester Royal Hospital, Worcester, UK.  
Address reprint requests to Dr. Saravana. E-mail:  
[adersh555saravana@hotmail.com](mailto:adersh555saravana@hotmail.com)

## REFERENCES

1. Swaak A. Anemia of chronic disease in patients with rheumatoid arthritis: aspects of prevalence, outcome, diagnosis and the effect of treatment on disease activity. *J Rheumatol* 2006;33:1467-8.
2. Greer JP, Foerster J, Lukens JN, et al. *Wintrobe's clinical haematology*. 11th ed. Philadelphia: Lippincott, Williams & Wilkins; 2004:962.
3. Garrett S, Worwood M. Zinc protoporphyrin and iron-deficient erythropoiesis. *Acta Haematol* 1994;91:21-5.
4. Hershko C, Konijn AM, Link G, Moreb J, Grauer F, Weissenberg E. Combined use of zinc protoporphyrin, mean corpuscular volume and haemoglobin measurements for classifying microcytic RBC disorders in children and young adults. *Clin Lab Haematol* 1985;7:259-69.
5. Wong SS, Qutishat AS, Lange J, Gornet TG, Buja LM. Detection of iron-deficiency anemia in hospitalized patients by zinc protoporphyrin. *Clin Chim Acta* 1996;244:91-101.
6. Hastka J, Lasserre JJ, Schwarzbeck A, Strauch M, Hehlmann R. Zinc protoporphyrin in anemia of chronic disorders. *Blood* 1993;81:1200-4.

## Dr. Swaak replies

To the Editor:

I read with interest the letter by Saravana and Rai in reaction to the editorial Anemia of Chronic Disease in Patients with RA. The question raised by Saravana and Rai is very important, related to which test is the best method for detection of iron-deficiency erythropoiesis (IDE) in patients with RA. Next to the question, which test could also predict the eventual effect on iron supplementation in restoring the anemia. In the past different methods were proposed and investigated: the measurement of the percentage of hypochromic red blood cells, content of hemoglobin in reticulocytes, soluble transferrin receptor, ferritin levels, and zinc protoporphyrin (ZPP) levels.

Presently, serum ferritin levels are the most common test in daily practice. The remark by Saravana and Rai that serum ferritin level is not a reliable indicator of iron deficiency, because it behaves as an acute phase reactant, is partly correct. However, by defining a cutoff  $< 50 \mu\text{g/l}$  we were able to show that this value correlated with the results obtained in bone marrow smears (no stainable iron), but also with the effect of iron supplementation. In this way the use of serum ferritin levels in RA was validated. In a recent study<sup>1</sup> ZPP, the soluble transferrin receptor, and the hemoglobin content of reticulocytes were investigated as a diagnostic and prognostic parameter in RA patients with anemia of chronic disease. In our study the value of serum ferritin was confirmed, and no additional benefit of the other measures for predicting or monitoring IDE was shown. To claim that a test can

be used for the diagnosis of IDE, the test has to be validated in the defined disease. For example, in patients with renal disease no significant correlation could be demonstrated between ZPP levels and IDE<sup>2-4</sup>. In these studies it was concluded that ZPP could not be used to predict the erythropoietic response to iron supplementation.

The same holds true for serum ferritin levels; however, in these studies a cutoff value of < 100 µg/l was defined for IDE. But it should be stressed that patients undergoing dialysis often showed raised serum ferritin levels, which is not explained. Still, a weak correlation could be demonstrated in another study<sup>5</sup>. Therefore, it should be stressed that for every disease the defined measure has to be validated. In this way the ZPP levels are not investigated in a prospective way in RA patients with anemia of chronic disease and IDE.

ANTONIUS J.G. SWAAK, MD, Department of Rheumatology, Ruwaard van Putten Ziekenhuis, Rotterdam, The Netherlands. E-mail: swaak@rpz.nl

## REFERENCES

1. Arndt U, Kaltwasser JP, Gottschalk R, Hoelzer D, Moller B. Correction of iron-deficient erythropoiesis in the treatment of anemia of chronic disease with recombinant human erythropoietin. *Ann Hematol* 2005;84:159-66.
2. Garrett S, Worwood M. Zinc protoporphyrin and iron-deficient erythropoiesis. *Acta Haematol* 1994;91:21-5.
3. Baldus M, Walter H, Thies K, et al. Transferrin receptor assay and zinc protoporphyrin as markers of iron-deficient erythropoiesis in end-stage renal disease patients. *Clin Nephrol* 1998;49:186-92.
4. Braun J, Hammerschmidt M, Schreiber M, Heidler R, Horl WH. Is zinc protoporphyrin an indicator of iron-deficient erythropoiesis in maintenance haemodialysis patients? *Nephrol Dial Transplant* 1996;11:492-7.
5. Braun J, Lindner K, Schreiber M, Heidler RA, Horl WH. Percentage of hypochromic red blood cells as predictor of erythropoietic and iron response after i.v. iron supplementation in maintenance haemodialysis patients. *Nephrol Dial Transplant* 1997;12:1173-81.

---

## Tumor Necrosis Factor (TNF) Can Paradoxically Increase on Etanercept Treatment, Occasionally Contributing to TNF-Mediated Disease

To the Editor:

Sari, *et al*<sup>1</sup> described a 34-year-old woman with a 3 year history of rheumatoid arthritis (RA), who developed psoriasis when given etanercept; the psoriasis resolved on cessation of etanercept. When etanercept was restarted the psoriasis returned. The psoriasis again resolved on cessation of etanercept. Etanercept is a treatment approved by the US Food and Drug Administration for RA, juvenile RA, ankylosing spondylitis, psoriatic arthritis (PsA), and psoriasis itself<sup>2</sup>. Tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) is a signaling molecule, 17 kDa in its soluble form (sTNF), 26 kDa as a transmembrane form (tmTNF). TNF maps to chromosome 6p21.3. TNF has emerged as an important inflammatory cytokine implicated in a number of inflammatory diseases or diseases with significant inflammatory component, including Crohn's disease, congestive heart failure (CHF), RA, and psoriasis, among a number of others. In psoriasis, TNF is abnormally released from cells in the skin in a constitutive manner — inducing production of other cytokines and chemokines that act to mediate an overly active autoimmune response<sup>3</sup>.

Etanercept is a 934 amino acid wholly-human protein, roughly 150 kDa total. It consists of an IgG Fc portion fused to 2 TNF receptor molecules (specifically, TNF-R2, synonymous with p75). It was introduced in late

1998 as the first drug in its class — TNF antagonizing agents — for the treatment of RA. Since then, its use has only expanded. We describe the apparent paradox of a drug, approved for treating psoriasis, apparently causing it.

In 1999, Moreland, *et al* reported from a randomized controlled trial that etanercept had significant benefit in improving signs and symptoms of RA<sup>4</sup>. Another study in 2004 showed equally impressive results, with RA patients significantly improving after starting etanercept treatment<sup>5</sup>. Etanercept was first reported to have had benefit in patients with PsA in 2000, in a 12 week study, where 73% of patients responded to etanercept therapy compared with only 13% of placebo-treated controls. This study also reported 25% of patients with psoriasis achieved a 75% improvement in psoriasis activity score compared with none in the placebo group<sup>6</sup>. It is important to note that PsA and psoriasis often occur together; about a third of patients with psoriasis have PsA, and most patients with PsA have coincident skin involvement. PsA represents an arthropathy that follows any of a number of specific patterns. Nail lesions, pitting edema, and ocular involvement are common<sup>7</sup>. Psoriasis is largely confined to the skin, with large silvery and scaly plaques; small, guttate lesions; pustular lesions (the most life-threatening form, associated with fever, malaise, diarrhea, hypocalcemia, leukocytosis, and liver failure); inverse psoriasis (extensor surfaces — knees, elbows, lower back, and scalp — spared; covered surfaces — axillary, inguinal, perineal, genital, gluteal — involved); and nail psoriasis<sup>8</sup>.

While etanercept is widely, and we believe correctly, understood to be an anti-TNF agent, it is possible that it may, at times, be increasing the levels of the very cytokine that it is designed to downregulate. At least 7 studies have shown an increase in serum TNF levels during etanercept treatment<sup>9-15</sup>.

Tsimberidou, *et al*<sup>9</sup> administered 25 mg of subcutaneous etanercept twice weekly to 10 patients with refractory multiple myeloma, and TNF concentrations were shown to rise significantly; it was concluded that etanercept had no anti-multiple myeloma activity.

Suffredini, *et al*<sup>10</sup> studied etanercept's effects on endotoxemia in 18 healthy volunteers (6 given placebo, 6 given low-dose etanercept, 6 given high-dose etanercept) and concluded that the drug markedly increased TNF levels in a dose-dependent fashion.

Zou, *et al* described upregulation of TNF secretion on administration of etanercept<sup>11</sup>. They studied<sup>12</sup> cytokine effects of etanercept in 10 patients with ankylosing spondylitis and found upregulation of serum TNF levels even in those patients achieving clinical benefit.

Madhusudan, *et al*<sup>13</sup> investigated the effects of etanercept in patients with progressive metastatic breast cancer that was refractory to conventional therapy, and determined that TNF levels were elevated within 24 hours of etanercept therapy — an elevation that persisted throughout the course of etanercept treatment in all patients who received the drug.

Nowlan, *et al*<sup>14</sup> studied etanercept as a potential treatment for TNF-receptor associated periodic syndrome (TRAPS), a type of hereditary periodic fever, and found that 8 patients with TRAPS who were given etanercept had increased levels of TNF.

Finally, Eason, *et al*<sup>15</sup> studied the use of etanercept in 6 patients given OKT3, an immunosuppressive agent that targets the T cell receptor (TCR/CD3) complex and works to prevent activation of T lymphocytes, helping to mitigate the potential for rejection after transplantation. They found that TNF levels were elevated post-etanercept, although they also observed clinical benefits of preserved renal function and less OKT3-mediated side effects in those who had elevation of circulating TNF.

Although Sari, *et al* did not monitor their patient's serum TNF levels, we believe studies cited above indicate that etanercept could well have caused an increase in TNF that contributed in generating her psoriatic symptoms.

It is important to note that in all of these studies, TNF that is biologically or immunologically active, that is active in immune and cellular signaling, is not necessarily the same as that detectable by anti-TNF antibodies by ELISA. TNF bound to etanercept or other carrier molecules can still

be present and detectable in the circulation but be unable to mediate biological, physiological, immunological, or inflammatory effects. The half-life of natural sTNF in circulation is variously estimated to be between 3 and 30 minutes. By administering etanercept it has been shown that this half-life is lengthened. Although sTNF bound by etanercept is not usually able to exert its physiological signaling effects, it may sometimes do so, either by dissociation from or while still retained by etanercept.

De novo generation of TNF mediated disease is not unheard of during etanercept treatment, and other published cases will be reviewed below. A third possibility is reviewed below, where etanercept, simply by removing sTNF signaling, can increase TNF mediated effects.

An explanation of the mechanism of etanercept increasing TNF has been reviewed<sup>16</sup>. Briefly, sTNF or tmTNF mediates its action through 2 outer cell-membrane receptors, TNF-R1 (weighted toward proapoptotic and antiinflammatory actions) and TNF-R2 (weighted toward antiapoptotic and proinflammatory actions). sTNF preferentially binds TNF-R1 over TNF-R2, while tmTNF binds and stimulates TNF-R1 and TNF-R2 equally well. Etanercept preferentially binds sTNF, preventing it from binding to TNF receptors, but shows little binding to, and therefore little inhibition of, signaling by tmTNF<sup>17</sup>. Since sTNF mediated downstream actions tend to be preferentially proapoptotic and antiinflammatory via the TNF-R1 pathway, tm-TNF is therefore left unopposed. A state of relative shift of weighting from TNF-R1 toward TNF-R2 occurs, resulting in a shift toward an antiapoptotic, proinflammatory state. By this mechanism, it is conceivable that etanercept actually increases TNF levels, and in some cases, as Sari, *et al* learned, may even cause the afflictions it is designed to treat.

TNF signaling is central to the pathology of Crohn's disease and is thought to play a part in CHF. A double-blinded placebo-controlled study<sup>18</sup> showed that etanercept was not effective for treatment of Crohn's disease. However, at least 2 studies describe cases of initial presentation of Crohn's disease after administration of etanercept for other reasons<sup>19,20</sup>; in neither case were TNF levels monitored.

From 1999 to 2001, etanercept was evaluated in 2 large randomized double-blinded placebo-controlled trials in CHF, where TNF and other inflammation related cytokines were seen to be elevated. Both studies concluded that etanercept was not efficacious, and one found etanercept use was associated with worsened mortality and increased hospitalizations. This association was dose related but did not reach statistical significance<sup>21</sup>.

There have been a number of case reports of CHF associated with etanercept use; Kwon, *et al* reviewed 29 cases of etanercept use that were associated with CHF onset: 4 of these patients were less than 50 years of age and had new-onset heart failure<sup>22</sup>. They concluded that TNF antagonists may indeed induce new-onset heart failure in a fraction of patients.

We conclude that elevated levels of biologically active TNF can occasionally occur with etanercept therapy. Three possible mechanisms for this are described. Etanercept induced elevation of TNF signaling may at times generate TNF mediated disease. Etanercept has benefit in lowering pain, increasing energy level, and improving quality of life in patients with RA and ankylosing spondylitis. But use of etanercept can be a concern because of an associated increase in TNF. We would advocate at least monitoring TNF levels detectable by ELISA, if not biologically active TNF. The former is easily available through specialized testing laboratories. The use of etanercept with caution is warranted, another example that understanding all effects of an administered drug should be kept in mind when treating the patient.

AJAY BHATIA, MD, Department of Psychiatry, The Ohio State University, Harding Hospital, 1670 Upham Drive, Columbus, Ohio 43210, E-mail: ajay\_bhatia2@yahoo.com; RICHARD E. KAST, MD, Department of Psychiatry, University of Vermont, 2 Church Street, Burlington, Vermont 05403, USA.

## REFERENCES

- Sari I, Akar S, Birlik M, et al. Anti-tumor necrosis factor- $\alpha$ -induced psoriasis. *J Rheumatol* 2006;33:1411-4.
- Hochberg MC, Lebowitz MG, Plevy SE. The benefit/risk profile of TNF-blocking agents: Findings of a consensus panel. *Semin Arthritis Rheum* 2005;34:819-36.
- Kupper TS. Immunologic targets in psoriasis. *New Engl J Med* 2003;349:1987-90.
- Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized controlled trial. *Ann Intern Med* 1999;130:478-86.
- Keystone EC, Schiff MH, Kremer JM, et al. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis — results of a multicenter, randomized, double-blind, placebo-controlled trial. *Arthritis Rheum* 2004;50:353-63.
- Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis — a randomized controlled trial. *Lancet* 2000;356:385-90.
- Lebowitz MG. Advances in psoriasis. *Arch Dermatol* 2005;141:1589-90.
- Schon MP, Boehnke WH. Psoriasis. *N Engl J Med* 2005; 352:1899-912.
- Tsimberidou AM, Waddelow T, Kantarjian HM, Albitar M, Giles FJ. Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNF alpha levels during treatment. *Leuk Res* 2003;27:375-80.
- Suffredini AF, Reda D, Banks SM, et al. Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. *J Immunol* 1995;155:5038-45.
- Zou JX, Braun J, Sieper J. Immunological basis for the use of TNF-alpha blocking agents in ankylosing spondylitis and immunological changes during treatment. *Clin Exp Rheumatol* 2002;20 Suppl:S34-7.
- Zou J, Rudwaleit M, Brandt J, et al. Up-regulation of the production of TNF-alpha and IFN-gamma by T cells in ankylosing spondylitis during treatment with etanercept. *Ann Rheum Dis* 2003;62:561-4.
- Madhusudan S, Foster M, Muthuramalingam SR, et al. A phase II study of etanercept (Enbrel), a TNF-alpha inhibitor in patients with metastatic breast cancer. *Clin Cancer Res* 2004;10:6528-34.
- Nowlan ML, Drewe E, Bulsara H, et al. Systemic cytokine levels and the effects of etanercept in TNF receptor-associated periodic syndrome (TRAPS) involving a C33Y mutation in TNFRSF1A. *Rheumatology Oxford* 2006;45:31-7.
- Eason JD, Pascual M, Wee S, et al. Evaluation of recombinant human soluble dimeric tumor necrosis factor receptor for prevention of OKT3-associated acute clinical syndrome. *Transplantation* 1996;61:224-8.
- Kast RE. Evidence of a mechanism by which etanercept increased TNF-alpha in multiple myeloma: New insights into the biology of TNF-alpha giving new treatment opportunities — the role of bupropion. *Leukemia Res* 2005;29:1459-63.
- Cianci R, Cammarota G, Raducci F, et al. The impact of biological agents interfering with receptor/ligand binding in the immune system. *Eur Rev Med Pharmacol Sci* 2005;9:305-14.
- Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. *Gastroenterology* 2001;121:1088-94.
- Oh J, Arkfield DG, Horwitz DA. Development of Crohn's disease in a patient taking etanercept. *J Rheumatol* 2005;32:752-3.
- Ruemmele FM, Prieur AM, Talbot C, et al. Development of Crohn's disease during anti-TNF-alpha therapy in a child with



juvenile idiopathic arthritis. *J Pediatr Gastroenterol Nutr* 2004;39:203-6.

21. Anker SD, Coates AJ. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWEL, and ATTACH. *Int J Cardiol* 2002;86: 123-30.
22. Kwon HJ, Cote TR, Cuffe MS, et al. Case reports of heart failure after therapy with tumor necrosis factor antagonist. *Ann Intern Med* 2003;138:807-11.

### Drs. Sari and Akkoc reply

To the Editor:

We appreciate Bhatia and Kast's interest in our case report and welcome their valuable comments. They argue that etanercept treatment can sometimes lead to increased tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) concentrations that may occasionally contribute to occurrence of TNF mediated disease, as in the case we described<sup>1</sup>.

They state there have been at least 7 studies showing an increase in TNF levels during etanercept treatment<sup>2-8</sup>. One report<sup>7</sup> actually reviewed the results of another study that was cited by them and also in our case report<sup>6</sup>. This study suggested an increase in the number of interferon- $\gamma$  (IFN- $\gamma$ ) and TNF- $\alpha$ -secreting T cells after nonspecific antigen stimulation after etanercept therapy in patients with ankylosing spondylitis. However, no data of serum TNF levels were given in that study.

The rest of the studies were mostly performed in patients with non-rheumatic conditions including myeloma<sup>5</sup>, breast cancer<sup>2</sup>, or renal transplant<sup>8</sup>, or in healthy volunteers given endotoxin<sup>4</sup>. These studies and another<sup>3</sup> conducted in patients with TNF-receptor associated periodic syndrome (TRAPS)<sup>3</sup> all reported increased levels of immunoreactive TNF. In 3 of these studies TNF bioactivity was measured by cytotoxicity assays and was found not to be increased<sup>3,4,8</sup>. Preclinical and clinical studies have demonstrated that etanercept prolongs the half-life of TNF<sup>8,9</sup>, and increased TNF levels observed in these studies are probably due to the carrier effect of etanercept.

Bhatia and Kast claim that etanercept-bound soluble TNF may sometimes exert its physiological signaling effects either by dissociation from etanercept or while still retained by it. However, this is very unlikely considering that TNF must be present for extended periods of time to achieve maximal biologic activity<sup>10</sup>. The development of psoriasis in our patient in the presence of marked improvement of arthritic symptoms (which are certainly also TNF mediated) also contradicts their hypothesis, suggesting a role for increased TNF levels in the circulation in the occurrence of psoriasis in our patient<sup>1</sup>. Occurrence of psoriasis or psoriasiform lesions after anti-TNF therapy, despite a good clinical response in arthritic symptoms, has also been observed by others<sup>10a</sup>.

Psoriasis has been reported not only with etanercept therapy, but also with infliximab and adalimumab, which have not been shown to lead to increased TNF levels in the serum. Interestingly, our patient who developed psoriasis after etanercept therapy did not develop any psoriatic lesion after infliximab within a followup of 15 months. We pointed out in our report that etanercept<sup>6</sup>, but not infliximab<sup>11</sup>, has been shown to upregulate local secretions of TNF- $\alpha$  and IFN- $\gamma$ , and proposed that this differential effect of the 2 TNF inhibitors could provide an explanation for the occurrence of psoriasis in our patient under treatment with etanercept, but not infliximab. However, there are reports of other cases that developed psoriasis with infliximab but not with etanercept<sup>1</sup>. It is likely that different mechanisms may play a role in different patients.

We agree that etanercept treatment may be associated with other TNF mediated diseases, such as Crohn's<sup>12</sup>, in which infliximab is efficacious<sup>13</sup>. Uveitis is another condition that can be successfully treated with infliximab, but that can occur as an adverse effect of etanercept<sup>14</sup>. However, worsening of congestive heart failure (CHF) has been reported with both

TNF inhibitors<sup>15</sup>. The review Bhatia and Kast cite describing 4 cases of new-onset CHF associated with etanercept use in patients under age 50 also reports 6 cases associated with infliximab therapy<sup>16</sup>. Moreover, a randomized controlled trial with infliximab for treatment of CHF was also stopped early due to increased morbidity and mortality<sup>17</sup>.

We believe the increased TNF levels reported in some studies cannot alone explain the occurrence of the paradoxical adverse effects such as psoriasis that have been reported not only with etanercept, but also with the other TNF inhibitors. We believe monitoring patients under etanercept therapy for detectable TNF levels is of questionable clinical value at best, and probably not necessary.

ISMAIL SARI, MD, Specialist of Internal Medicine; NURULLAH AKKOC, MD, Professor of Internal Medicine, Department of Internal Medicine, Division of Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey.

Address reprint requests to Dr. N. Akkoc, Dokuz Eylul Universitesi Tip Fakultesi, Ic Hastaliklari AD, Romatoloji BD, 35340 Inciralti, Izmir, Turkey. E-mail: murullah.akkoc@deu.edu.tr

### REFERENCES

1. Sari I, Akar S, Birlik M, Sis B, Onen F, Akkoc N. Anti-tumor necrosis factor-alpha-induced psoriasis. *J Rheumatol* 2006;33:1411-4.
2. Madhusudan S, Foster M, Muthuramalingam SR, et al. A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer. *Clin Cancer Res* 2004;10:6528-34.
3. Nowlan ML, Drewe E, Bulsara H, et al. Systemic cytokine levels and the effects of etanercept in TNF receptor-associated periodic syndrome (TRAPS) involving a C33Y mutation in TNFRSF1A. *Rheumatology Oxford* 2006;45:31-7.
4. Suffredini AF, Reda D, Banks SM, Tropea M, Agosti JM, Miller R. Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. *J Immunol* 1995;155:5038-45.
5. Tsimberidou AM, Waddelow T, Kantarjian HM, Albitar M, Giles FJ. Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNF alpha levels during treatment. *Leukemia Res* 2003;27:375-80.
6. Zou J, Rudwaleit M, Brandt J, Thiel A, Braun J, Sieper J. Upregulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept. *Ann Rheum Dis* 2003;62:561-4.
7. Zou JX, Braun J, Sieper J. Immunological basis for the use of TNF- $\alpha$ -blocking agents in ankylosing spondylitis and immunological changes during treatment. *Clin Exp Rheumatol* 2002;20 Suppl 28:S34-7.
8. Eason JD, Pascual M, Wee S, et al. Evaluation of recombinant human soluble dimeric tumor necrosis factor receptor for prevention of OKT3-associated acute clinical syndrome. *Transplantation* 1996;61:224-8.
9. Mohler KM, Torrance DS, Smith CA, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. *J Immunol* 1993;151:1548-61.
10. Engelberts I, Moller A, Leeuwenberg JF, van der Linden CJ, Buurman WA. Administration of tumor necrosis factor alpha (TNF alpha) inhibitors after exposure to TNF alpha prevents development of the maximal biological effect: an argument for clinical treatment with TNF alpha inhibitors. *J Surg Res* 1992;53:510-4.

- 10a. Kary S, Worm M, Audring H, et al. New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists. *Ann Rheum Dis* 2006;65:405-7.
11. Zou J, Rudwaleit M, Brandt J, Thiel A, Braun J, Sieper J. Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab. *Arthritis Rheum* 2003;48:780-90.
12. Oh J, Arkfeld DG, Horwitz DA. Development of Crohn's disease in a patient taking etanercept. *J Rheumatol* 2005;32:752-3.
13. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. *New Engl J Med* 1997;337:1029-35.
14. Taban M, Dupps WJ, Mandell B, Perez VL. Etanercept (enbrel)-associated inflammatory eye disease: case report and review of the literature. *Ocul Immunol Inflamm* 2006;14:145-50.
15. Mann DL. Targeted anticytokine therapy and the failing heart. *Am J Cardiol* 2005;95:9C-16C; 38C-40C.
16. Kwon HJ, Cote TR, Cuffe MS, Kramer JM, Braun MM. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. *Ann Intern Med* 2003;138:807-11.
17. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate to severe heart failure: results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. *Circulation* 2003;107:3133-40.

## Whiplash and Widespread Pain

*To the Editor:*

We understand that Sterling, as a physiotherapist, in her discussions of hypersensitivity and whiplash<sup>1</sup>, would find clinical tests of a subjective nature (i.e., perceptions of pain responses to stimuli and pain thresholds) useful in daily practice. That is the very nature of much of current physiotherapy practice — focusing on pain levels and attempting to quantify pain. As physicians, our training encourages us to ask different questions of the chronic pain problem, such as how patients' environment (litigation, compensation), expectations of recovery, and psychosocial characteristics shape their clinical presentation and prognosis. This approach is increasingly important in many medical conditions, and can be no less so in a condition that is defined less by injury (no one, not even physiotherapists, know of what whiplash injury consists) than by widespread, systemic illness inexplicable by pathology alone<sup>2</sup>. The concern with focusing on a theory that links hypersensitivity and outcomes is that this focuses clinicians and their patients on injury.

Sterling, in reviewing risk factors for chronic pain following a motor vehicle accident (MVA) appears to have missed the boat (for an Australian this could be a long sentence). The most single important factor determining whether or not chronic whiplash-associated disorder (WAD) develops after an MVA is where one lives, something that could not be tested in the Manchester study. Some cultures are the Petri dishes for chronic pain. Although the studies are few, and more are needed to extend the results, results from Germany, Lithuania, and Greece, when examined in detail in relation to similar studies conducted in whiplash cultures (i.e., North America and Australia), clearly define culture, not crash, as the chief determinant of outcome<sup>3</sup>. Still, it could be argued that, within a whiplash culture, not all collision victims develop chronic pain. It is thus worthwhile to identify prognostic factors. Yet, here too, we feel the most globally important factors, such as expectation of recovery, are being overlooked by

researchers who cling to injury-based theories because their training and experience do not allow them to step out of those unidimensional models.

Current work in Saskatchewan (data in submission), for example, where litigation has been eliminated, and more than 100 variables are accounted for in multivariate analysis, indicates that what the injured person expects in terms of recovery in turn determines time to self-reported recovery. We find this approach at identifying predictors of outcomes much more compelling, being based on large, unselected populations, without the selection bias that the small sample size of Sterling, *et al* introduces. Many more factors are accounted for and there is a more extensive inclusion of those at risk for chronic pain. We find research on hypersensitivity has been conducted without any population based approaches, without a defined gold standard for hypersensitivity, and with no known sensitivities or specificities for any of the tests conducted (Ferrari<sup>3</sup>, p. 112). This narrowly focused, rudimentary research strays into metaphysics and moreover smacks of the 19th century explanation for chronic pain — nervous irritation<sup>4</sup>. With railway spine in the 19th century, and then in 2 separate occasions with whiplash earlier in our history, the diagnosis of nervous irritation has been championed in one form or another<sup>4</sup>. Whatever medicine has learned over the years about the importance of psychological factors in chronic pain tends to be ignored or downplayed as nonetiologic. What seems most tempting about concepts like nervous irritation then, and hypersensitivity now, what places these terms in the theorist's spotlight, is the emotional connotations of these terms, making them ideal to use with laypeople, and gaining ready acceptance (almost as terms of empathy) in a suffering patient.

Hypersensitivity is, quite plainly, a distraction to the truth, and a disservice to our patients, as we cause them to focus on an unidentifiable problem within their nervous system arising from an unidentifiable injury, rather than focusing on how their beliefs (and those of our society), expectations, and victimization within the litigation and treatment industries have led them to chronic pain.

ROBERT FERRARI, MD, Department of Medicine; ANTHONY S. RUSSELL, MD, Department of Rheumatic Diseases, University of Alberta. Address reprint requests to Dr. R. Ferrari, University of Alberta Hospital—Medicine, Room 2G2.06, 8440-112 Street, Edmonton, Alberta T6G 2B7, Canada. E-mail: rferrari@shaw.ca

## REFERENCES

1. Sterling M. Identifying those at risk of developing persistent pain following a motor vehicle collision. *J Rheumatol* 2006;33:838-9.
2. Ferrari R, Russell AS, Carroll LJ, Cassidy JD. A re-examination of the whiplash-associated disorders (WAD) as a systemic illness. *Ann Rheum Dis* 2005;64:1337-42.
3. Ferrari R. The whiplash encyclopedia. The facts and myths of whiplash. 2nd ed. Sudbury, MA: Jones and Bartlett Publishers; 2005:121-45.
4. Ferrari R, Shorter E. From railway spine to whiplash — the recycling of nervous irritation. *Med Sci Monit* 2003;9:HY27-37.

## Dr. Sterling replies

*To the Editor:*

Once again we hear from Ferrari and Russell, who cite only their opinion-based papers, thereby negating any attempt to engage them in valid scientific debate in a prestigious peer-reviewed journal such as this. They believe that, "[T]he most single important factor determining whether or not chronic WAD develops after an MVA is where one lives."

At odds with this belief is a recent systematic review on prognosis following whiplash injury that failed to identify culture as a predictor of poor outcome<sup>1</sup>. The Greek study<sup>2</sup> quoted by Ferrari and Russell was included in this review, but was not rated as a particularly high quality study. The

German study to which they refer comprised 43 subjects with acute whiplash injury, of whom only 32 (74%) participants attended for followup assessment<sup>3</sup> — which can hardly be considered as a population based study!

While a full and clear picture of these “whiplash” conditions is yet to be elucidated, one fact is quite apparent. They are remarkably complex, with diverse clinical manifestations that can include motor dysfunction, psychological distress, and, in some patients, evidence of sensory dysfunction.

The phenomenon of sensory hypersensitivity to a series of stimuli, both noxious and non-noxious, has been unequivocally demonstrated in numerous cohorts, in the acute and chronic contexts, by researchers from many disciplines involved in pain medicine (including physiotherapists)<sup>4-10</sup>.

Two studies, one conducted in Denmark and the other in Australia, have shown that sensory hypersensitivity, often in association with other prognostic indicators such as pain intensity and some psychosocial factors, is predictive of poor recovery<sup>6,11</sup>.

While it is thought that the sensory hypersensitivity is a reflection of altered nociception, interpretation of many of the quantitative sensory tests used in clinical research is necessarily dependent upon the patients’ cognitive responses. However, evidence of spinal cord hyperexcitability as measured by reflex muscle responses following direct electrical stimulation to a peripheral nerve has been demonstrated in both chronic whiplash and other painful musculoskeletal conditions<sup>12,13</sup>. This reflex response is robust in the presence of anxiety and catastrophization and provides what can be considered as “objective” evidence of central hyperexcitability<sup>14-16</sup>.

As a side issue, it is disappointing that Ferrari and Russell have chosen to launch an ad hominem attack upon the physiotherapy profession from their self-appointed position as “trained physicians” who are apparently custodians of the truth in these matters. They would be better advised to heed the words of William J. Mayo, who wisely said: “Scientific truth which I formerly thought of as fixed, as though it could be weighed and measured, is changeable. Add a fact, change the outlook, and you have a new truth. Truth is a constant variable. We seek it, we find it, our viewpoint changes, and the truth changes with it”<sup>17</sup>.

MICHELE STERLING, PhD, MPhy, Bphly, Senior Lecturer, Division of Physiotherapy, School of Health and Rehabilitation Sciences, The University of Queensland, St. Lucia, Australia 4072.

## REFERENCES

1. Scholten-Peeters G, Verhagen A, Bekkering G, et al. Prognostic factors of whiplash associated disorders: a systematic review of prospective cohort studies. *Pain* 2003;104:303-22.
2. Partheni M, Constantoyannis C, Ferrari R, et al. A prospective study of the outcome of acute whiplash injury in Greece. *Clin Exp Rheumatol* 2000;18:67-70.
3. Richter M, Ferrari R, Otte D, et al. Correlation of findings, collision parameters and psychological factors in the outcome of whiplash associated disorders. *J Neurol Neurosurg Psychiatry* 2004;75:758-64.
4. Sheather-Reid R, Cohen M. Psychophysical evidence for a neuropathic component of chronic neck pain. *Pain* 1998;75:341-7.
5. Moog M, Quintner J, Hall T, Zusman M. The late whiplash syndrome: a psychophysical study. *Eur J Pain* 2002;6:283-94.
6. Kasch H, Qerama E, Bach F, Jensen T. Reduced cold pressor pain tolerance in non-recovered whiplash patients: a 1 year prospective study. *Eur J Pain* 2004;9:561-9.
7. Koelbaek-Johansen M, Graven-Nielsen T, Schou-Olesen A, Arendt-Nielsen L. Muscular hyperalgesia and referred pain in chronic whiplash syndrome. *Pain* 1999;83:229-34.
8. Sterling M, Jull G, Vicenzino B, Kenardy J. Sensory hypersensitivity occurs soon after whiplash injury and is associated with poor recovery. *Pain* 2003;104:509-17.

9. Scott D, Jull G, Sterling M. Sensory hypersensitivity is a feature of chronic whiplash associated disorders but not chronic idiopathic neck pain. *Clin J Pain* 2005;21:175-81.
10. Curatolo M, Petersen-Felix S, Arendt-Nielsen L, et al. Central hypersensitivity in chronic pain after whiplash injury. *Clin J Pain* 2001;17:306-15.
11. Sterling M, Jull G, Kenardy J. Physical and psychological predictors of outcome following whiplash injury maintain predictive capacity at long term follow-up. *Pain* 2006;122:102-8.
12. Sandrini G, Arrigo A, Bono G, Nappi G. The nociceptive flexion reflex as a tool for exploring pain control systems in headache and other pain syndromes. *Cephalalgia* 1993;13:21-7.
13. Banic B, Petersen-Felix S, Andersen O, et al. Evidence for spinal cord hypersensitivity in chronic pain after whiplash injury and in fibromyalgia. *Pain* 2004;107:7-15.
14. Sterling M, Kenardy J, Souvlis T, et al. Sensory hypersensitivity and psychological distress following whiplash injury: Is there a relationship? *Pain across the lifespan [abstract]*. Australian Pain Society 26th annual conference. Melbourne: APS; 2006.
15. French D, France C, France J, Arnott L. The influence of acute anxiety on assessment of nociceptive flexion reflex thresholds in healthy young adults. *Pain* 2005;114:358-63.
16. France C, France J, Absi M, et al. Catastrophizing is related to pain ratings, but not nociceptive flexion reflex threshold. *Pain* 2002;99:459-63.
17. Mayo W. Seventieth birthday anniversary of William J. Mayo. *Annals of Surgery* 1931;94:799-800.

---

## Alberta Rodeo Riders Do Not Develop Late Whiplash

To the Editor:

We were surprised to see that Shannon, *et al*'s paper regarding the comparative rates of chronic whiplash in Alberta rodeo athletes versus members of the rodeo audience merited publication<sup>1</sup>. Despite these authors' claim that “we have no reason to believe that the distribution of such injuries should be strikingly different in these 2 groups”, we would have surmised that the peer reviewers of this article would have easily discovered the reason that escaped Shannon, *et al* and yet would have been readily apparent to most lay readers of the study. We find the authors' conclusions just as publication-worthy as those of a study of the average height of NBA basketball players versus game attendees, with the conclusion that the difference of more than a foot in height is best explained by the theory that the attendees must be lacking in nutrition. In a similar vein, Shannon, *et al* explained the difference in symptom duration between rodeo athletes and audience members as the result of a specious biopsychosocial theory that sidesteps the enormous amount of literature indicating an organic etiology of most chronic whiplash symptoms, instead blaming the chronic symptoms on an irrational fear of whiplash injury in the patient<sup>2-10</sup>.

In arriving at their biopsychosocial explanation for their findings, Shannon, *et al* managed to overlook the fact that rodeo athletes are self-selected ultra-hardy members of the population, located at the furthest right extreme of the injury susceptibility bell curve. While few laypeople are aware of the definitions of the epidemiologic terms “bias” and “confounding,” most are aware of the intuitive concept that professional athletes should not be compared to nonprofessional athletes for the characteristics that make them most likely to become professional athletes: physical prowess and injury resistance. It is rather surprising that the reviewers who green-lighted this paper for publication were not more attentive. In our opinion, this paper should not have been published in its current form.



CHRISTOPHER CENTENO, MD, Centeno-Schultz Clinic, Westminster, Colorado; MICHAEL D. FREEMAN, MD, Oregon Health and Science University School of Medicine, Department of Public Health and Preventive Medicine, Salem, Oregon, USA. Address reprint requests to Dr. C. Centeno, Centeno-Schultz Clinic, 11080 Circle Point Road, Bldg. 2, Ste. 140, Westminster, Colorado 80020.  
E-mail: centenooffice@centenoclinic.com



## REFERENCES

1. Shannon AL, Ferrari R, Russell AS. Alberta rodeo athletes do not develop the chronic whiplash syndrome. *J Rheumatol* 2006; 33:975-7.
2. Barnsley L, Lord SM, Wallis BJ, Bogduk N. The prevalence of chronic cervical zygapophysial joint pain after whiplash. *Spine* 1995;20:20-5; discussion 26.
3. Krakenes J, Kaale BR, Moen G, Nordli H, Gilhus NE, Rorvik J. MRI assessment of the alar ligaments in the late stage of whiplash injury — a study of structural abnormalities and observer agreement. *Neuroradiology* 2002;44:617-24.
4. Kristjansson E, Leivseth G, Brinckmann P, Frobin W. Increased sagittal plane segmental motion in the lower cervical spine in women with chronic whiplash-associated disorders, grades I-II: a case-control study using a new measurement protocol. *Spine* 2003;28:2215-21.
5. Lord SM, Barnsley L, Wallis BJ, Bogduk N. Chronic cervical zygapophysial joint pain after whiplash. A placebo-controlled prevalence study. *Spine* 1996;21:1737-44; discussion 1744-5.
6. Panjabi MM, Ito S, Pearson AM, Ivancic PC. Injury mechanisms of the cervical intervertebral disc during simulated whiplash. *Spine* 2004;29:1217-25.
7. Siegmund GP, Myers BS, Davis MB, Bohnet HF, Winkelstein BA. Mechanical evidence of cervical facet capsule injury during whiplash: a cadaveric study using combined shear, compression, and extension loading. *Spine* 2001;26:2095-101.
8. Sterling M, Jull G, Vicenzino B, Kenardy J. Sensory hypersensitivity occurs soon after whiplash injury and is associated with poor recovery. *Pain* 2003;104:509-17.
9. Treleaven J, Jull G, Sterling M. Dizziness and unsteadiness following whiplash injury: characteristic features and relationship with cervical joint position error. *J Rehabil Med* 2003;35:36-43.
10. Wallis BJ, Lord SM, Bogduk N. Resolution of psychological distress of whiplash patients following treatment by radiofrequency neurotomy: a randomised, double-blind, placebo-controlled trial. *Pain* 1997;73:15-22.

## Drs. Ferrari and Russell reply

*To the Editor:*

Drs. Centeno and Freeman seem to “get” the point of our study: there is a significant psychosocial difference between athletes and nonathletes, and this may lead to vastly different whiplash injury outcomes. Whiplash injury is thus not like a leg fracture: while coping style may assist in some aspects of rehabilitation from a fracture once it is healed, being an athlete probably does little else to speed recovery from a fracture. A form of “mental toughness” or other psychosocial differences between athletes and nonathletes is more likely to be relevant in whiplash injury recovery, and this aspect is apparent from our study. As even Drs. Centeno and Freeman managed to get this, we are not surprised the reviewers should as well.

ROBERT FERRARI, MD, Department of Medicine;  
ANTHONY S. RUSSELL, MD, Department of Rheumatic Diseases,  
University of Alberta. Address reprint requests to Dr. R. Ferrari,  
University of Alberta Hospital—Medicine, Room 2G2.06, 8440-112  
Street, Edmonton, Alberta T6G 2B7, Canada. E-mail: rferrari@shaw.ca

## RS<sub>3</sub>PE Syndrome: Bad or Good Prognosis?

*To the Editor:*

We read with great interest the article by Russell regarding the potential relationship between remitting seronegative symmetrical synovitis with pitting edema (RS<sub>3</sub>PE) syndrome and neoplasia<sup>1</sup>. As the author concluded, prospective followup studies would help clarify longterm risk of neoplasia in patients with RS<sub>3</sub>PE syndrome.

Since 1988 we have followed 15 cases of RS<sub>3</sub>PE syndrome in a standardized manner at a single university institution. Reports on 12 cases have been published, and we describe here the clinical, immunogenetic, and development characteristics of the whole cohort, adding 3 new cases seen in the last 3 years<sup>2</sup>. All cases fulfilled the main features of RS<sub>3</sub>PE syndrome given in the seminal article by McCarty, *et al*<sup>3</sup>. Our study protocol for these cases has been published, and these 3 new cases were followed according to it<sup>2</sup>.

The main results are shown in Table 1. No patient needed disease modifying antirheumatic drugs to achieve remission.

Although initially RS<sub>3</sub>PE syndrome appeared to be a well characterized entity with a good prognosis, in the last few years several groups have questioned this view, as the syndrome has been associated with several solid tumors, hematological diseases, immunostimulants, infections, and rheumatic conditions<sup>4</sup>. Since its initial description, most cases have shown clinical, developmental, and immunogenetic features that distinguished RS<sub>3</sub>PE from the 2 most closely related conditions, late-onset rheumatoid arthritis (RA) and polymyalgia rheumatica (PMR)<sup>3</sup>. In that sense, an association between RS<sub>3</sub>PE and HLA-DR antigens has not yet emerged, whereas both RA and PMR are correlated with HLA-DR4, although the putative epitopes responsible for these 2 conditions differ in location<sup>5</sup>. In our view, RS<sub>3</sub>PE syndrome may be seen from 3 different perspectives. The first plausible explanation is that this entity may be a type of reactive arthritis favored by some HLA antigens, such as B27 and B7-CREG antigens. In the present series, 46% showed at least one of these antigens, but we did not investigate the presence of habitual pathogens for this type of arthritis. Also favoring this notion, a late-onset undifferentiated spondyloarthropathy syndrome resembling the features of RS<sub>3</sub>PE has been described in men over 50 years of age, and over time some of them developed ankylosing spondylitis<sup>6</sup>. A second conception has been supported by some authors, that both PMR and RS<sub>3</sub>PE syndrome are similar conditions, emphasizing the idea that the presence of distal edemas only indicates a better prognosis and not a real difference between the 2<sup>7</sup>. However, we must keep in mind that the HLA profile of these 2 conditions is quite different, as we cited above and also show here. Finally, a third conception is that the condition could involve a type of paraneoplastic syndrome linked to the synthesis of a factor such as interleukin 6, among others<sup>8</sup>. This view is supported by some recent case reports and small series, but we found no case of neoplasia in the present report. We found one patient who presented an IgG-kappa monoclonal paraproteinemia, but he has developed neither multiple myeloma nor malignant disease over a followup of 9 years. Two of our patients died, one with acute myocardial infarction and one with a cerebral hemorrhage.

In our opinion, RS<sub>3</sub>PE syndrome is a well characterized entity with a spectrum of severity ranging from the less severe and most common forms,

represented by cases with one attack and no relapse; then an intermediate form, in which there are relapses successfully treated with corticosteroids (20% of the present series); and in the extreme of the spectrum, cases associated with neoplasia, which fortunately represent a minority among RS<sub>3</sub>PE cases.

In our context, RS<sub>3</sub>PE still remains a definite condition with an excellent prognosis, but some questions remain unsolved. For example, which patients will have a benign, self-limiting course and which will have more protracted disease, and more importantly, whether the disease course and the risk of neoplasia can be predicted on the basis of the initial presentation or the HLA profile.

RUBEN QUEIRO, MD, PhD; MERCEDES ALPERI, MD; JOSE LUIS RIESTRA, MD, PhD; JAVIER BALLINA, MD, PhD, Rheumatology Service, Hospital Universitario Central de Asturias, C/ Celestino Villamil s/n, 33006 Oviedo, Asturias, Spain. Address reprint requests to Dr. Queiro. E-mail: ruquei@mixmail.com

#### REFERENCES

1. Russell EB. Remitting seronegative symmetrical synovitis with pitting edema syndrome: followup for neoplasia. *J Rheumatol* 2005;32:1760-1.
2. Queiro R. RS<sub>3</sub>PE syndrome: a clinical and immunogenetical study. *Rheumatol Int* 2004;24:103-5.
3. McCarty DJ, O'Duffy JD, Pearson L, Hunter JB. Remitting seronegative symmetrical synovitis with pitting edema. RS<sub>3</sub>PE syndrome. *JAMA* 1985;254:2763-7.
4. Schaeverbeke T, Fatout E, Marce S, et al. Remitting seronegative symmetrical synovitis with pitting edema: disease or syndrome? *Ann Rheum Dis* 1995;54:681-4.
5. Weyand CM, Hunder NN, Hicok KC, Hunder GG, Goronzy JJ. HLA-DRB1 alleles in polymyalgia rheumatica, giant cell arteritis, and rheumatoid arthritis. *Arthritis Rheum* 1994;37:514-20.
6. Olivieri I, Padula A, Pierro A, Favaro L, Oranges GS, Ferri S. Late onset undifferentiated seronegative spondyloarthropathy. *J Rheumatol* 1995;22:899-903.
7. Cantini F, Salvarani C, Olivieri I, et al. Remitting seronegative symmetrical synovitis with pitting oedema (RS<sub>3</sub>PE) syndrome: a prospective follow up and magnetic resonance imaging study. *Ann Rheum Dis* 1999;58:230-6.
8. Sibilía J, Friess S, Schaeverbeke T, et al. Remitting seronegative symmetrical synovitis with pitting edema (RS<sub>3</sub>PE): a form of paraneoplastic polyarthritis? *J Rheumatol* 1999;26:115-20.